(Reuters) – A genetically engineered smallpox vaccine reduced the risk of death for patients with advanced liver cancer by nearly 60 percent in a mid-stage study, prompting the launch of a later-stage trial.
Recent Posts Categories Best Trends Business Financial Hot News Hot trends Info News